|
|
 |
|
Viewing report
|
|
|
|
Cancer Drugs with Apoptotic Targets in Development
Biophoenix Limited, July 2010, Pages: 32
Cancer drugs with apoptotic targets in development, updated July 2010, provides key information on 138 targeted apoptotic drugs in anticancer development by a total of 104 companies. These drugs are directed at the products of one or more of over 40 genes involved in apoptosis (programmed cell death).
Most current cancer therapies, including chemotherapeutic agents, work by inducing apoptosis in cancer cells. However, many cancer cells are resistant or develop resistance to these agents. A promising new direction for drug development involves approaches designed to overcome treatment resistance due to over-expression of anti-apoptotic genes or downregulation of pro-apoptotic genes.
Apoptotic drugs in anticancer development were identified using a wide variety of sources, including the publishers proprietary company database, various online databases, the scientific literature, academic and company websites, company press releases, web-based news searches, industry newsletters, and conference proceedings. Apoptotic anticancer drugs are characterized in terms of their target(s), development status, originator company/licensee, therapy type, mode of action, and indication.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Apoptosis 2009: Opportunities in Cancer and Other Diseases
Drug Delivery in Cancer - Technologies, Markets and Companies
Cancer Drug Resistance
Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success
Lipid Nanocarriers in Cancer Diagnosis and Therapy
Competitor Analysis - PI3K-AKT-mTOR Inhibitors
Personalized Medicine - Scientific and Commercial Aspects
Oncology Pipeline Database
The Complete Guide to Targeted Therapies in Oncology: A World Review
Alzheimer Disease - New Drugs, Markets and Companies
|
|
|
|
